Preliminary safety and biological efficacy studies of ethyl pyruvate in normal mature horses.
Authors: Schroeder E L, Holcombe S J, Cook V L, James M D, Gandy J C, Hauptman J G, Sordillo L M
Journal: Equine veterinary journal
Summary
# Editorial Summary: Ethyl Pyruvate in Equine Medicine Endotoxaemia represents a critical complication in equine colic and sepsis, driving significant morbidity and mortality despite current therapeutic interventions. Schroeder and colleagues conducted preliminary safety and efficacy testing of ethyl pyruvate—a novel anti-inflammatory agent—in healthy mature horses, building on promising results from multiple animal models (rodents, swine, sheep and dogs) where the compound demonstrated improved survival rates in severe sepsis and intestinal ischaemia–reperfusion injury. Their investigation established baseline safety parameters and biological responses in the target species before progressing to clinical applications in diseased animals. The findings are particularly relevant for practitioners managing acute colics and septic cases, where controlling excessive inflammatory cascades triggered by endotoxin translocation remains a significant therapeutic challenge. Further clinical trials in affected horses will determine whether ethyl pyruvate can meaningfully reduce mortality in naturally occurring endotoxaemia, potentially expanding the anti-inflammatory toolkit beyond current corticosteroid and non-steroidal options.
Read the full abstract on PubMed
Practical Takeaways
- •Ethyl pyruvate is a novel anti-inflammatory agent that may have clinical potential for treating endotoxaemia-related conditions in horses with colic or sepsis, though clinical trials are still needed
- •This preliminary work provides a foundation for further investigation into therapeutic options for conditions with high morbidity and mortality in equine practice
- •Results from preclinical models in other species suggest mechanistic benefit, but efficacy and safety protocols specific to horses require additional study
Key Findings
- •Ethyl pyruvate demonstrated anti-inflammatory properties in preclinical models of severe sepsis and endotoxaemia across multiple species including rodents, swine, sheep and dogs
- •Study was preliminary safety and efficacy evaluation in normal mature horses, suggesting potential therapeutic application for equine colic and sepsis management
- •Previous animal models showed improved survival outcomes with ethyl pyruvate treatment in conditions relevant to equine disease